Otwarty dostęp

Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study

Nina Turnsek

Nina Turnsek

Department of Medical Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
Wyszukaj tego autora
Sciendo|Google Scholar
Turnsek, Nina
, 
Rok Devjak

Rok Devjak

  • Department of Medical Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
  • Faculty of Medicine, University of LjubljanaLjubljana, Slovenia
Wyszukaj tego autora
Sciendo|Google Scholar
Devjak, Rok
, 
Natalija Edelbaher

Natalija Edelbaher

Department of Pulmonary Diseases, University Medical Centre MariborPohorje, Slovenia
Wyszukaj tego autora
Sciendo|Google Scholar
Edelbaher, Natalija
, 
Ilonka Osrajnik

Ilonka Osrajnik

Department of Pulmonary Diseases, University Medical Centre MariborPohorje, Slovenia
Wyszukaj tego autora
Sciendo|Google Scholar
Osrajnik, Ilonka
, 
Mojca Unk

Mojca Unk

Department of Medical Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
Wyszukaj tego autora
Sciendo|Google Scholar
Unk, Mojca
, 
Dusanka Vidovic

Dusanka Vidovic

Department of Pulmonary Diseases, University Medical Centre MariborPohorje, Slovenia
Wyszukaj tego autora
Sciendo|Google Scholar
Vidovic, Dusanka
, 
Tina Jeric

Tina Jeric

AstraZeneca UK Limited, Branch office in SloveniaLjubljana, Slovenia
Wyszukaj tego autora
Sciendo|Google Scholar
Jeric, Tina
 oraz 
Urska Janzic

Urska Janzic

Department of Medical Oncology, University Clinic GolnikGolnik, Slovenia
Wyszukaj tego autora
Sciendo|Google Scholar
Janzic, Urska
  
14 sie 2022
Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study's Cover Image
O artykule
Poprzedni artykuł
Następny artykuł
Zacytuj
Pobierz okładkę
Kategoria artykułu: research article
Data publikacji: 14 sie 2022
Zakres stron: 371 - 379
Otrzymano: 31 sty 2022
Przyjęty: 07 kwi 2022
DOI: https://doi.org/10.2478/raon-2022-0025
Słowa kluczowe
© 2022 Nina Turnsek, Rok Devjak, Natalija Edelbaher, Ilonka Osrajnik, Mojca Unk, Dusanka Vidovic, Tina Jeric, Urska Janzic, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Figure 1

(A) Kaplan-Meier curves for median real-world progression free survival on first-line (1L) epidermal growth factor (EGFR) tyrosine kinase inhibitors (TKIs) therapy. (B) Kaplan-Meier curves for median overall survival from start of 1L EGFR TKI therapy. Censored patients are indicated with a cross. CI = confidence interval; OS = overall survival; rwPFS = real-world progression-free survival
(A) Kaplan-Meier curves for median real-world progression free survival on first-line (1L) epidermal growth factor (EGFR) tyrosine kinase inhibitors (TKIs) therapy. (B) Kaplan-Meier curves for median overall survival from start of 1L EGFR TKI therapy. Censored patients are indicated with a cross. CI = confidence interval; OS = overall survival; rwPFS = real-world progression-free survival

Figure 2

Treatment patterns patients in with locally advanced or metastatic epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC) treated with first-line (1L) first-/second-generation (1G/2G) EGFR tyrosine kinase inhibitors (TKIs). Note that multiple treatments could have been administered at each line of treatment. * Targeted therapy besides afatinib, erlotinib, gefitinib and osimertinib (1L: not specified; 3L: crizotinib); 2L = second-line; 3L =third-line; IO = immuno-oncology
Treatment patterns patients in with locally advanced or metastatic epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC) treated with first-line (1L) first-/second-generation (1G/2G) EGFR tyrosine kinase inhibitors (TKIs). Note that multiple treatments could have been administered at each line of treatment. * Targeted therapy besides afatinib, erlotinib, gefitinib and osimertinib (1L: not specified; 3L: crizotinib); 2L = second-line; 3L =third-line; IO = immuno-oncology

Figure 3

Attrition rates at first-line (1L), second-line (2L) and third-line (3L) in patients with locally advanced or metastatic epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC).
Attrition rates at first-line (1L), second-line (2L) and third-line (3L) in patients with locally advanced or metastatic epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC).

Clinical characteristics at the time of initial NSCLC diagnosis

Characteristic N = 120 n (%)
Smoking history
      Current smoker 7 (6)
      Former smoker 33 (28)
      Never smoker 76 (63)
      Unknown 4 (3)
ECOG performance status
      0 28 (23)
      1 62 (52)
      2 22 (18)
      3 6 (5)
      4 1 (1)
      Unknown 1 (1)
      Stage at initial diagnosis
      Early stage (I-II) 13 (11)
      Limited regional (IIIA) 4 (3)
      Locally advanced (IIIB) 0
      Metastatic (IV) 103 (86)
Site of distant metastases
      Adrenal 12 (10)
      Bone 54 (45)
      Brain 33 (28)
      Liver 19 (16)
      Lung 60 (50)
      Lymph nodes 60 (50)
      Peritoneal 2 (2)
      Pleura 38 (32)
      Skin/soft tissue 3 (3)
      Other* 10 (8)
Język:
Angielski
Częstotliwość wydawania:
4 razy w roku
Dziedziny czasopisma:
Medycyna, Medycyna kliniczna, Medycyna wewnętrzna, Hematologia, onkologia, Radiologia
Kanał RSS czasopisma